Peel Hunt restated their buy rating on shares of Clinigen Group (LON:CLIN) in a report issued on Tuesday, June 4th, ThisIsMoney.Co.Uk reports.
A number of other equities analysts have also recently weighed in on CLIN. Royal Bank of Canada restated a top pick rating and set a GBX 1,640 ($21.43) price objective (up from GBX 1,470 ($19.21)) on shares of Clinigen Group in a research report on Wednesday, February 27th. Numis Securities reiterated a buy rating and issued a GBX 1,275 ($16.66) target price on shares of Clinigen Group in a research report on Wednesday, February 27th.
LON CLIN traded down GBX 3 ($0.04) during mid-day trading on Tuesday, reaching GBX 1,007 ($13.16). 346,720 shares of the stock were exchanged, compared to its average volume of 432,646. The business has a 50 day simple moving average of GBX 1,019.11. Clinigen Group has a 1 year low of GBX 716 ($9.36) and a 1 year high of GBX 1,069 ($13.97). The stock has a market cap of $1.33 billion and a P/E ratio of 50.60. The company has a quick ratio of 1.32, a current ratio of 1.54 and a debt-to-equity ratio of 56.71.
Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.
Read More: Trading Ex-Dividend
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.